NCT05683379Active, not recruiting
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to <25 Years
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 4 Jan 2023
- Start date
- 20 Dec 2022
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- REGENXBIO Inc.
- Diseases
- Duchenne muscular dystrophy
- NCT number
- NCT05683379
What you commit to
- Study type: Observational
- Planned participants: 200
- From 20 Dec 2022 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior participation in a gene therapy trial OR recipient of a gene therapy drug
Other
- Other inclusion/exclusion criteria apply
Who the study is looking for
- Males at least 0 to \<25 years of age
- Diagnosis of DMD
- Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements
Age in the registry: 0 years to 25 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rare Disease Research Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.